Human Monoclonal Antibody 2G12 Defines a Distinctive Neutralization Epitope on the Gp120 Glycoprotein of Human Immunodeficiency Virus Type 1

Overview

Journal J Virol

Publisher American Society for Microbiology

Date 1996 Feb 1

PMID 8551569

Citations 628

Authors

A Trkola

M Purtscher

T Muster

C Ballaun

A Buchacher

N Sullivan

K Srinivasan

J Sodroski

J P Moore

H Katinger

Affiliations

Soon will be listed here.

Abstract

We have isolated and characterized human monoclonal antibody 2G12 to the gp120 surface glycoprotein of human immunodeficiency virus type 1 (HIV-1). This antibody potently and broadly neutralizes primary and T-cell line-adapted clade B strains of HIV-1 in a peripheral blood mononuclear cell-based assay and inhibits syncytium formation in the AA-2 cell line. Furthermore, 2G12 possesses neutralizing activity against strains from clade A but not from clade E. Complement- and antibody-dependent cellular cytotoxicity-activating functions of 2G12 were also defined. The gp120 epitope recognized by 2G12 was found to be distinctive; binding of 2G12 to LAI recombinant gp120 was abolished by amino acid substitutions removing N-linked carbohydrates in the C2, C3, V4, and C4 regions of gp120. This gp120 mutant recognition pattern has not previously been observed, indicating that the 2G12 epitope is unusual. consistent with this, antibodies able to block 2G12 binding to recombinant gp120 were not detected in significant quantities in 16 HIV-positive human serum samples.

Citing Articles

Assessing bnAb potency in the context of HIV-1 envelope conformational plasticity.

Foulkes C, Friedrich N, Ivan B, Stiegeler E, Magnus C, Schmidt D PLoS Pathog. 2025; 21(1):e1012825.

PMID: 39836706 PMC: 11774494. DOI: 10.1371/journal.ppat.1012825.

Cell-autonomous targeting of arabinogalactan by host immune factors inhibits mycobacterial growth.

Qin L, Xu J, Chen J, Wang S, Zheng R, Cui Z Elife. 2024; 13.

PMID: 39495223 PMC: 11534329. DOI: 10.7554/eLife.92737.

An explainable language model for antibody specificity prediction using curated influenza hemagglutinin antibodies.

Wang Y, Lv H, Teo Q, Lei R, Gopal A, Ouyang W Immunity. 2024; 57(10):2453-2465.e7.

PMID: 39163866 PMC: 11464180. DOI: 10.1016/j.immuni.2024.07.022.

Afucosylated broadly neutralizing antibodies enhance clearance of HIV-1 infected cells through cell-mediated killing.

de Taeye S, Schriek A, Umotoy J, Grobben M, Burger J, Sanders R Commun Biol. 2024; 7(1):964.

PMID: 39122901 PMC: 11316088. DOI: 10.1038/s42003-024-06659-8.

Membrane HIV-1 envelope glycoproteins stabilized more strongly in a pretriggered conformation than natural virus Envs.

Zhang Z, Anang S, Nguyen H, Fritschi C, Smith 3rd A, Sodroski J iScience. 2024; 27(7):110141.

PMID: 38979012 PMC: 11228805. DOI: 10.1016/j.isci.2024.110141.

References

Spear G, Sullivan B, Landay A, Lint T . Neutralization of human immunodeficiency virus type 1 by complement occurs by viral lysis. J Virol. 1990; 64(12):5869-73. PMC: 248749. DOI: 10.1128/JVI.64.12.5869-5873.1990. View

Sullivan N, Sun Y, Li J, Hofmann W, Sodroski J . Replicative function and neutralization sensitivity of envelope glycoproteins from primary and T-cell line-passaged human immunodeficiency virus type 1 isolates. J Virol. 1995; 69(7):4413-22. PMC: 189183. DOI: 10.1128/JVI.69.7.4413-4422.1995. View

Ho D, McKeating J, Li X, Moudgil T, Daar E, Sun N . Conformational epitope on gp120 important in CD4 binding and human immunodeficiency virus type 1 neutralization identified by a human monoclonal antibody. J Virol. 1991; 65(1):489-93. PMC: 240544. DOI: 10.1128/JVI.65.1.489-493.1991. View

Gorny M, Xu J, Gianakakos V, Karwowska S, Williams C, Sheppard H . Production of site-selected neutralizing human monoclonal antibodies against the third variable domain of the human immunodeficiency virus type 1 envelope glycoprotein. Proc Natl Acad Sci U S A. 1991; 88(8):3238-42. PMC: 51421. DOI: 10.1073/pnas.88.8.3238. View

Montefiori D, LEFKOWITZ Jr L, Keller R, Holmberg V, Sandstrom E, Phair J . Absence of a clinical correlation for complement-mediated, infection-enhancing antibodies in plasma or sera from HIV-1-infected individuals. Multicenter AIDS Cohort Study Group. AIDS. 1991; 5(5):513-7. DOI: 10.1097/00002030-199105000-00006. View

Thali M, Olshevsky U, Furman C, Gabuzda D, Posner M, Sodroski J . Characterization of a discontinuous human immunodeficiency virus type 1 gp120 epitope recognized by a broadly reactive neutralizing human monoclonal antibody. J Virol. 1991; 65(11):6188-93. PMC: 250310. DOI: 10.1128/JVI.65.11.6188-6193.1991. View

Ho D, Fung M, Cao Y, Li X, Sun C, Chang T . Another discontinuous epitope on glycoprotein gp120 that is important in human immunodeficiency virus type 1 neutralization is identified by a monoclonal antibody. Proc Natl Acad Sci U S A. 1991; 88(20):8949-52. PMC: 52628. DOI: 10.1073/pnas.88.20.8949. View

Steimer K, Scandella C, Skiles P, Haigwood N . Neutralization of divergent HIV-1 isolates by conformation-dependent human antibodies to Gp120. Science. 1991; 254(5028):105-8. DOI: 10.1126/science.1718036. View

Fung M, Sun C, GORDON W, Liou R, Chang T, Sun W . Identification and characterization of a neutralization site within the second variable region of human immunodeficiency virus type 1 gp120. J Virol. 1992; 66(2):848-56. PMC: 240785. DOI: 10.1128/JVI.66.2.848-856.1992. View

10.

Koup R, Robinson J, Nguyen Q, Pikora C, Blais B, Roskey A . Antibody-dependent cell-mediated cytotoxicity directed by a human monoclonal antibody reactive with gp120 of HIV-1. AIDS. 1991; 5(11):1309-14. DOI: 10.1097/00002030-199111000-00004. View

11.

Tilley S, Honnen W, Racho M, HILGARTNER M, Pinter A . A human monoclonal antibody against the CD4-binding site of HIV1 gp120 exhibits potent, broadly neutralizing activity. Res Virol. 1991; 142(4):247-59. DOI: 10.1016/0923-2516(91)90010-z. View

12.

Buchbinder A, Karwowska S, Gorny M, Burda S, Zolla-Pazner S . Synergy between human monoclonal antibodies to HIV extends their effective biologic activity against homologous and divergent strains. AIDS Res Hum Retroviruses. 1992; 8(4):425-7. DOI: 10.1089/aid.1992.8.425. View

13.

Thali M, Furman C, Ho D, Robinson J, Tilley S, Pinter A . Discontinuous, conserved neutralization epitopes overlapping the CD4-binding region of human immunodeficiency virus type 1 gp120 envelope glycoprotein. J Virol. 1992; 66(9):5635-41. PMC: 289129. DOI: 10.1128/JVI.66.9.5635-5641.1992. View

14.

Posner M, Elboim H, Cannon T, Cavacini L, Hideshima T . Functional activity of an HIV-1 neutralizing IgG human monoclonal antibody: ADCC and complement-mediated lysis. AIDS Res Hum Retroviruses. 1992; 8(5):553-8. DOI: 10.1089/aid.1992.8.553. View

15.

Langedijk J, Back N, BRUCK C, Francotte M, Goudsmit J, Meloen R . Comparison and fine mapping of both high and low neutralizing monoclonal antibodies against the principal neutralization domain of HIV-1. Arch Virol. 1992; 126(1-4):129-46. DOI: 10.1007/BF01309690. View

16.

Spear G, Carlson J, Jennings M, Takefman D, Landay A . Complement-mediated, antibody-dependent neutralizing titers of sera from asymptomatic and symptomatic HIV-infected individuals. AIDS. 1992; 6(9):1047. DOI: 10.1097/00002030-199209000-00027. View

17.

Spear G, Takefman D, Sullivan B, Landay A, Zolla-Pazner S . Complement activation by human monoclonal antibodies to human immunodeficiency virus. J Virol. 1993; 67(1):53-9. PMC: 237336. DOI: 10.1128/JVI.67.1.53-59.1993. View

18.

Posner M, Cavacini L, Emes C, Power J, Byrn R . Neutralization of HIV-1 by F105, a human monoclonal antibody to the CD4 binding site of gp120. J Acquir Immune Defic Syndr (1988). 1993; 6(1):7-14. View

19.

Moore J, Ho D . Antibodies to discontinuous or conformationally sensitive epitopes on the gp120 glycoprotein of human immunodeficiency virus type 1 are highly prevalent in sera of infected humans. J Virol. 1993; 67(2):863-75. PMC: 237440. DOI: 10.1128/JVI.67.2.863-875.1993. View

20.

Thali M, Moore J, Furman C, Charles M, Ho D, Robinson J . Characterization of conserved human immunodeficiency virus type 1 gp120 neutralization epitopes exposed upon gp120-CD4 binding. J Virol. 1993; 67(7):3978-88. PMC: 237765. DOI: 10.1128/JVI.67.7.3978-3988.1993. View